178 related articles for article (PubMed ID: 34873472)
1. CDKN1A/p21
Arnoff TE; El-Deiry WS
Am J Cancer Res; 2021; 11(11):5452-5471. PubMed ID: 34873472
[TBL] [Abstract][Full Text] [Related]
2. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
3. Truncating
Alhalabi O; Msaouel P
Am J Cancer Res; 2021; 11(12):6214-6217. PubMed ID: 35018253
[TBL] [Abstract][Full Text] [Related]
4. Differential Effects of Clinically Relevant N- versus C-Terminal Truncating CDKN1A Mutations on Cisplatin Sensitivity in Bladder Cancer.
Sikder RK; Ellithi M; Uzzo RN; Weader DJ; Metz AL; Behbahani A; McKenzie ER; El-Deiry WS; Abbosh PH
Mol Cancer Res; 2021 Mar; 19(3):403-413. PubMed ID: 33272936
[TBL] [Abstract][Full Text] [Related]
5. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
[TBL] [Abstract][Full Text] [Related]
6.
Yin M; Grivas P; Emamekhoo H; Mendiratta P; Ali S; Hsu J; Vasekar M; Drabick JJ; Pal S; Joshi M
Oncotarget; 2018 Mar; 9(24):16891-16898. PubMed ID: 29682192
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing of salivary high-grade neuroendocrine carcinomas identifies alterations in RB1 and the mTOR pathway.
Goyal B; Duncavage EJ; Martinez D; Lewis JS; Chernock RD
Exp Mol Pathol; 2014 Dec; 97(3):572-8. PubMed ID: 25446844
[TBL] [Abstract][Full Text] [Related]
8. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
[TBL] [Abstract][Full Text] [Related]
9. Genomic Characterization of Upper Tract Urothelial Carcinoma.
Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
[TBL] [Abstract][Full Text] [Related]
10. Bladder Cancer and Genetic Mutations.
Zhang X; Zhang Y
Cell Biochem Biophys; 2015 Sep; 73(1):65-9. PubMed ID: 27352265
[TBL] [Abstract][Full Text] [Related]
11. Bladder cancer genomics.
Siracusano S; Rizzetto R; Porcaro AB
Urologia; 2020 May; 87(2):49-56. PubMed ID: 31942831
[TBL] [Abstract][Full Text] [Related]
12. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response.
Glaser AP; Fantini D; Wang Y; Yu Y; Rimar KJ; Podojil JR; Miller SD; Meeks JJ
Oncotarget; 2018 Jan; 9(4):4537-4548. PubMed ID: 29435122
[TBL] [Abstract][Full Text] [Related]
13. Loss of CDKN1A mRNA and Protein Expression Are Independent Predictors of Poor Outcome in Chromophobe Renal Cell Carcinoma Patients.
Ohashi R; Angori S; Batavia AA; Rupp NJ; Ajioka Y; Schraml P; Moch H
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32079343
[TBL] [Abstract][Full Text] [Related]
14. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.
Harms PW; Hovelson DH; Cani AK; Omata K; Haller MJ; Wang ML; Arps D; Patel RM; Fullen DR; Wang M; Siddiqui J; Andea A; Tomlins SA
Hum Pathol; 2016 May; 51():25-31. PubMed ID: 27067779
[TBL] [Abstract][Full Text] [Related]
15. Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients.
Fantini D; Seiler R; Meeks JJ
Urol Oncol; 2019 Nov; 37(11):818-825. PubMed ID: 30446446
[TBL] [Abstract][Full Text] [Related]
16. Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Miron B; Hoffman-Censits JH; Anari F; O'Neill J; Geynisman DM; Zibelman MR; Kutikov A; Viterbo R; Greenberg RE; Chen D; Lallas CD; Trabulsi EJ; Alpaugh RK; Dulaimi E; Golemis EA; Uzzo R; Ross EA; Plimack ER
Eur Urol Oncol; 2020 Aug; 3(4):544-547. PubMed ID: 32165095
[TBL] [Abstract][Full Text] [Related]
17. SWI/SNF Alterations in Squamous Bladder Cancers.
Achenbach F; Rose M; Ortiz-Brüchle N; Seillier L; Knüchel R; Weyerer V; Hartmann A; Morsch R; Maurer A; Ecke TH; Garczyk S; Gaisa NT
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227989
[TBL] [Abstract][Full Text] [Related]
18. [Point somatic mutations in bladder cancer: key carcinogenesis events, diagnostic markers and therapeutic targets].
Mikhailenko DS; Nemtsova MV
Urologiia; 2016 Feb; (1):100-105. PubMed ID: 28247712
[TBL] [Abstract][Full Text] [Related]
19. Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer.
Bartkova J; Guldberg P; Grønbaek K; Koed K; Primdahl H; Møller K; Lukas J; Ørntoft TF; Bartek J
Oncogene; 2004 Nov; 23(52):8545-51. PubMed ID: 15361851
[TBL] [Abstract][Full Text] [Related]
20. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
